You are here

BCRF Grantee Since


Donor Recognition

The Estée Lauder Companies Brands Award in Memory of Evelyn H. Lauder

Area(s) of Focus

Fabrice Andre, MD, PhD

Research Director, Head of INSERM Unit U981
INSERM (Institut National des Sciences et de la Recherche Médicale)
Associate Professor, Department of Medical Oncology
Institut Gustave Roussy
Villejuif, France

Current Research

Each breast cancer is characterized by a unique pattern of genomic alterations. Targeting the genomic alteration responsible for transforming cells from benign to malignant should stop cancer progression, but studies suggest that such targeted treatments may lead to drug resistance in some breast cancer patients. The goal of Dr. André’s BCRF project is to identify genetic biomarkers associated with resistance to targeted therapies in metastatic breast cancer. His group is analyzing the DNA from patients who have been treated with a gene-targeted therapy to determine whether multiple DNA mutations within the different tumor cells make the tumors resistant to therapy. In the coming year, Dr. André will continue his work to identify predictive biomarkers and analyze gene mutations associated with sensitivity to mTOR and CDK4 inhibitors in patients with metastatic breast cancers. These studies will lead to better personalized therapies by identifying new genes involved in the development of breast cancer and potential drug combinations most likely to work in a specific subset of breast cancer patients.


Fabrice André MD, PhD, is an oncologist based at Gustave Roussy Cancer Cancer, Villejuif, France. He is Professor of Medicine at University Paris Sud. His BCRF research focuses on the characterisation of molecular alterations in metastatic breast cancers. He is leading several prospective trials that aim to show the clinical utility of genomic tests for patients with metastatic breast cancers. He is also leading development of targeted therapies in the same setting. He is the chair of INSERM Unit U981, a research team dedicated to target identification. He is Senior Editor Breast cancer section at Annals of Oncology.